Details of the Drug-Related molecule(s) Interaction Atlas

General Information of Drug (ID: DMB1NE2)

• Drug Name: Vixarelimab Drug Info
• Synonyms: RG6536

Indication

Disease Entry	ICD 11	Status	REF
Idiopathic pulmonary fibrosis	CB03.4	Phase 1	[1]
Pruritus	EC90	Phase 1	[2]

• Cross-matching ID: TTD Drug ID: DMB1NE2

Molecular Interaction Atlas of This Drug

Drug Therapeutic Target (DTT)

DTT Name	DTT ID	UniProt ID	MOA	REF
Oncostatin-M-specific receptor beta (OSMR)	TTAH0KM	OSMR_HUMAN	Not Available	[3]

References

• [1] ClinicalTrials.gov (NCT05785624) A Two-Cohort, Phase II, Multicenter, Randomized, Double-Blind, Parallel-Group, Placebo-Controlled Study Evaluating the Efficacy and Safety of Vixarelimab Compared With Placebo in Patients With Idiopathic Pulmonary Fibrosis and in Patients With Systemic Sclerosis-Associated Interstitial Lung Disease. U.S.National Institutes of Health.
• [2] ClinicalTrials.gov (NCT03816891) A Phase 2a/b, Randomized, Double-Blind, Placebo-Controlled Study to Investigate the Efficacy, Safety, Tolerability and Pharmacokinetics of KPL-716 in Reducing Pruritus in Subjects With Prurigo Nodularis. U.S.National Institutes of Health.
• [3] Efficacy and safety of vixarelimab, a human monoclonal oncostatin M receptor beta antibody, in moderate-to-severe prurigo nodularis: a randomised, double-blind, placebo-controlled, phase 2a study. EClinicalMedicine. 2023 Feb 3;57:101826.